Skip to main content
Top
Literature
1.
go back to reference Chatziralli I, Theodossiadis G, Kabanarou SA, Parikakis E, Xirou T, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. Graefes Arch Clin Exp Ophthalmol [Epub ahead of print]. doi:10.1007/s00417-017-3719-5 Chatziralli I, Theodossiadis G, Kabanarou SA, Parikakis E, Xirou T, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. Graefes Arch Clin Exp Ophthalmol [Epub ahead of print]. doi:10.​1007/​s00417-017-3719-5
2.
go back to reference Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed
3.
go back to reference Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gilles M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex Geneva Study Group (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118:2453–2560CrossRefPubMed Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gilles M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex Geneva Study Group (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118:2453–2560CrossRefPubMed
4.
go back to reference Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P (2017) Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina [Epub ahead of print]. doi:10.1097/IAE.0000000000001579 Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P (2017) Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina [Epub ahead of print]. doi:10.​1097/​IAE.​0000000000001579​
Metadata
Title
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: special remarks of the RANIDEX study
Authors
I. Chatziralli
G. Theodossiadis
S. A. Kabanarou
P. Theodossiadis
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3750-6

Other articles of this Issue 10/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2017 Go to the issue